Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

about

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

Item

http://www.wikidata.org/entity/Q38383481

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

@en

type

Item

label

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

@en

prefLabel

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

@en

P1476

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

@en

P2093

Anna Patrikidou

http://www.w3.org/2001/XMLSchema#string

Charikleia Destouni

http://www.w3.org/2001/XMLSchema#string

Konstantinos Vahtsevanos

http://www.w3.org/2001/XMLSchema#string

Kyriaki Kitikidou

http://www.w3.org/2001/XMLSchema#string

Rosalia Maria Valeri

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Cancer statistics, 2012

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration

Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

P2888

s12253-015-0017-6

P304

401-411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12253-015-0017-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284185089

http://www.w3.org/2001/XMLSchema#string

P698

26581612

http://www.w3.org/2001/XMLSchema#string